血液系统恶性肿瘤中的 RNA 甲基化及其与其他表观遗传修饰的相互作用。
RNA methylation in hematological malignancies and its interactions with other epigenetic modifications.
机构信息
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
出版信息
Leukemia. 2021 May;35(5):1243-1257. doi: 10.1038/s41375-021-01225-1. Epub 2021 Mar 25.
Abstract
Hematological malignancies are a class of malignant neoplasms attributed to abnormal differentiation of hematopoietic stem cells (HSCs). The systemic involvement, poor prognosis, chemotherapy resistance, and recurrence common in hematological malignancies urge researchers to look for novel treatment targets and mechanisms. In recent years, epigenetic abnormalities have been shown to play a vital role in tumorigenesis and progression in hematological malignancies. In addition to DNA methylation and histone modifications, which are most studied, RNA methylation has become increasingly significant. In this review, we elaborate recent advances in the understanding of RNA modification in the pathogenesis, diagnosis and molecular targeted therapies of hematological malignancies and discuss its intricate interactions with other epigenetic modifications, including DNA methylation, histone modifications and noncoding RNAs.
摘要
血液系统恶性肿瘤是一类起源于造血干细胞（HSCs）异常分化的恶性肿瘤。血液系统恶性肿瘤常见全身性累及、预后不良、化疗耐药和复发，这促使研究人员寻找新的治疗靶点和机制。近年来，表观遗传异常已被证明在血液系统恶性肿瘤的发生和进展中起着至关重要的作用。除了研究最多的 DNA 甲基化和组蛋白修饰外，RNA 甲基化也变得越来越重要。在这篇综述中，我们详细阐述了 RNA 修饰在血液系统恶性肿瘤发病机制、诊断和分子靶向治疗中的最新研究进展，并讨论了其与其他表观遗传修饰（包括 DNA 甲基化、组蛋白修饰和非编码 RNA）的复杂相互作用。
相似文献
1
RNA methylation in hematological malignancies and its interactions with other epigenetic modifications.血液系统恶性肿瘤中的 RNA 甲基化及其与其他表观遗传修饰的相互作用。
Leukemia. 2021 May;35(5):1243-1257. doi: 10.1038/s41375-021-01225-1. Epub 2021 Mar 25.
2
Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies.组蛋白修饰及其在血液系统恶性肿瘤中的治疗靶点的影响。
Int J Mol Sci. 2022 Nov 7;23(21):13657. doi: 10.3390/ijms232113657.
3
Epigenetic programming contributes to development of drug resistance in hematological malignancies.表观遗传编程有助于血液系统恶性肿瘤耐药的发生。
Front Biosci (Landmark Ed). 2015 Jan 1;20(4):728-42. doi: 10.2741/4333.
4
Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer.非编码 RNA 在食管癌表观遗传修饰中的作用。
Biomed Pharmacother. 2019 Sep;117:109192. doi: 10.1016/j.biopha.2019.109192. Epub 2019 Jul 11.
5
The DNA methylation landscape of hematological malignancies: an update.血液系统恶性肿瘤的 DNA 甲基化图谱：更新。
Mol Oncol. 2020 Aug;14(8):1616-1639. doi: 10.1002/1878-0261.12744. Epub 2020 Jul 3.
6
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.造血过程中的表观遗传调控及其在血液系统恶性肿瘤靶向治疗中的意义。
Signal Transduct Target Ther. 2023 Feb 17;8(1):71. doi: 10.1038/s41392-023-01342-6.
7
Transgenerational inheritance: how impacts to the epigenetic and genetic information of parents affect offspring health.跨代遗传：父母的表观遗传和遗传信息如何影响后代的健康。
Hum Reprod Update. 2019 Sep 11;25(5):518-540. doi: 10.1093/humupd/dmz017.
8
[A primer for epigenetics of hematological malignancies].[血液系统恶性肿瘤表观遗传学入门]
Rinsho Ketsueki. 2016;57(10):1835-1844. doi: 10.11406/rinketsu.57.1835.
9
EHA scientific workshop report: the role of epigenetics in hematological malignancies.欧洲血液学协会科学研讨会报告：表观遗传学在血液系统恶性肿瘤中的作用
Epigenetics. 2007 Apr-Jun;2(2):71-9. doi: 10.4161/epi.2.2.4425. Epub 2007 May 14.
10
Novel epigenetic therapies in hematological malignancies: Current status and beyond.血液系统恶性肿瘤中的新型表观遗传学治疗：现状及未来。
Semin Cancer Biol. 2018 Aug;51:198-210. doi: 10.1016/j.semcancer.2017.07.005. Epub 2017 Aug 4.
引用本文的文献
1
METTL13 is essential for the survival of acute myeloid leukemia cells by regulating MYC.METTL13通过调控MYC对急性髓系白血病细胞的存活至关重要。
Cell Death Discov. 2025 May 17;11(1):240. doi: 10.1038/s41420-025-02512-x.
2
[Advancements in artificial intelligence for the precise diagnosis and treatment of hematological malignancies].人工智能在血液系统恶性肿瘤精准诊断与治疗中的进展
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):186-192. doi: 10.3760/cma.j.cn121090-20241022-00409.
3
Basic and applied research progress of TRAIL in hematologic malignancies.TRAIL在血液系统恶性肿瘤中的基础与应用研究进展
Blood Sci. 2025 Mar 11;7(2):e00221. doi: 10.1097/BS9.0000000000000221. eCollection 2025 Jun.
4
Critical roles and clinical perspectives of RNA methylation in cancer.RNA甲基化在癌症中的关键作用及临床前景
MedComm (2020). 2024 May 7;5(5):e559. doi: 10.1002/mco2.559. eCollection 2024 May.
5
Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation.YTHDC1 与 METTL3/METTL14 结合亲和力受损导致 DDX41 突变的骨髓增生异常肿瘤中 R 环积累。
Leukemia. 2024 Jun;38(6):1353-1364. doi: 10.1038/s41375-024-02228-4. Epub 2024 Mar 21.
6
Prognostic value of RNA methylation-related genes in gastric adenocarcinoma based on bioinformatics.基于生物信息学的RNA甲基化相关基因在胃腺癌中的预后价值
PeerJ. 2024 Feb 29;12:e16951. doi: 10.7717/peerj.16951. eCollection 2024.
7
The role of RNA modification in urological cancers: mechanisms and clinical potential.RNA修饰在泌尿系统癌症中的作用：机制与临床潜力
Discov Oncol. 2023 Dec 20;14(1):235. doi: 10.1007/s12672-023-00843-8.
8
Diagnostic Values of METTL1-Related Genes and Immune Characteristics in Systemic Lupus Erythematosus.METTL1相关基因在系统性红斑狼疮中的诊断价值及免疫特征
J Inflamm Res. 2023 Nov 17;16:5367-5383. doi: 10.2147/JIR.S431628. eCollection 2023.
9
RNA modifications-a regulatory dimension yet to be deciphered in immunity.RNA修饰——免疫中有待破解的调控维度。
Genes Immun. 2023 Dec;24(6):281-282. doi: 10.1038/s41435-023-00228-5.
10
Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia.评价 6-巯基嘌呤相关不耐受患儿中 FTO 多态性与急性淋巴细胞白血病的关系。
Cancer Chemother Pharmacol. 2023 Jul;92(1):51-56. doi: 10.1007/s00280-023-04546-3. Epub 2023 May 31.
本文引用的文献
1
Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice.c-Myc 杂合不足在维持小鼠造血干细胞中的作用。
Blood. 2021 Feb 4;137(5):610-623. doi: 10.1182/blood.2019004688.
2
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.mRNA m6A 阅读器 YTHDF2 抑制促炎途径并维持造血干细胞功能。
J Exp Med. 2021 Mar 1;218(3). doi: 10.1084/jem.20200829.
3
Interplay of mA and H3K27 trimethylation restrains inflammation during bacterial infection.mA 和 H3K27 三甲基化的相互作用在细菌感染过程中抑制炎症反应。
Sci Adv. 2020 Aug 19;6(34):eaba0647. doi: 10.1126/sciadv.aba0647. eCollection 2020 Aug.
4
A novel N6-methyladenosine (m6A)-dependent fate decision for the lncRNA THOR.一种新型的 N6-甲基腺苷（m6A）依赖的长非编码 RNA THOR 的命运决定。
Cell Death Dis. 2020 Aug 13;11(8):613. doi: 10.1038/s41419-020-02833-y.
5
N-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2.N6-甲基腺苷共转录指导组蛋白 H3K9me2 的去甲基化。
Nat Genet. 2020 Sep;52(9):870-877. doi: 10.1038/s41588-020-0677-3. Epub 2020 Aug 10.
6
TACC3 expression as a prognostic factor in aggressive types of adult T-cell leukemia/lymphoma patients.TACC3 表达作为侵袭性成人 T 细胞白血病/淋巴瘤患者的预后因素。
Int J Lab Hematol. 2020 Dec;42(6):842-848. doi: 10.1111/ijlh.13289. Epub 2020 Aug 3.
7
LNC942 promoting METTL14-mediated mA methylation in breast cancer cell proliferation and progression.LNC942 促进乳腺癌细胞增殖和进展中的 METTL14 介导的 mA 甲基化。
Oncogene. 2020 Jul;39(31):5358-5372. doi: 10.1038/s41388-020-1338-9. Epub 2020 Jun 23.
8
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.靶向 FTO 抑制癌症干细胞维持和免疫逃逸。
Cancer Cell. 2020 Jul 13;38(1):79-96.e11. doi: 10.1016/j.ccell.2020.04.017. Epub 2020 Jun 11.
9
Prognostic values of YTHDF1 regulated negatively by mir-3436 in Glioma.YTHDF1 在胶质瘤中受 mir-3436 负调控的预后价值。
J Cell Mol Med. 2020 Jul;24(13):7538-7549. doi: 10.1111/jcmm.15382. Epub 2020 May 25.
10
LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.长链非编码 RNA SOX2OT 通过 ALKBH5 介导的表观遗传调控提高 SOX2 的表达，促进胶质母细胞瘤对替莫唑胺的耐药性。
Cell Death Dis. 2020 May 21;11(5):384. doi: 10.1038/s41419-020-2540-y.
Zotero 插件